Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Harderwijk – page 2

63 clinical trials in Harderwijk, The Netherlands. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Harderwijk at a glance
63
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

63 trials in Harderwijk

Open in trial search

Non-small cell lung cancer

Recruiting

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Pfizer Inc.

Chronic lymphocytic leukaemia+1

Recruiting

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Non-small cell lung cancer

Recruiting

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Human papilloma virus immunisation+1

Recruiting

Study on HPV Vaccine for Women with Vulvar HSIL: Evaluating the Effectiveness of Nonavalent HPV Vaccine in Preventing Recurrence of Vulvar High-Grade Lesions

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Plasma cell myeloma

Recruiting

Study on Treatment-Free Intervals for Newly Diagnosed Multiple Myeloma Patients Using Daratumumab, Lenalidomide, and Dexamethasone

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Diffuse large B-cell lymphoma

Recruiting

Study on Preventing Heart Problems in Patients with Diffuse Large B-Cell Lymphoma Using Dexrazoxane and a Drug Combination

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Colorectal cancer metastatic

Recruiting

Dose-Reduced Oxaliplatin and Drug Combination Study for Older Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Capecitabine
  • Sponsor:Leiden University Medical Center

Non-small cell lung cancer

Recruiting

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:MK-1084
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Recruiting

Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Non-small cell lung cancer

Not yet recruiting

Study of Izalontamab Brengitecan versus Platinum-based Chemotherapy for Patients with EGFR-mutated Non-small Cell Lung Cancer after EGFR Inhibitor Treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

K-ras gene mutation+2

Not yet recruiting

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Harderwijk

What the registry says about research in the country

01 Oncology - Lung Cancer

Multiple innovative trials focusing on non-small cell lung cancer (NSCLC) treatments, evaluating new therapeutic combinations and targeted approaches for different disease stages.

  • Advanced and Metastatic NSCLC
  • Early-Stage Treatment
  • Targeted Therapies

Studies are investigating novel drug combinations and immunotherapy approaches to improve patient outcomes.

02 Hematologic Malignancies

Groundbreaking research in chronic lymphocytic leukemia (CLL) and lymphomas, exploring various treatment combinations and duration-optimized approaches.

  • First-line CLL Treatments
  • Novel Drug Combinations
  • Treatment Duration Studies

Focus on personalized treatment strategies and improved patient outcomes through innovative therapies.

03 Cardiovascular Research

Studies addressing atherosclerotic cardiovascular disease and heart failure prevention, testing new therapeutic approaches and preventive strategies.

  • Heart Failure Prevention
  • Cardiovascular Risk Management
  • Novel Therapeutic Agents

Emphasis on reducing major adverse cardiovascular events and improving patient outcomes.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.